Merus NV

Biohaven's Trop2-directed ADC BHV-1510 demonstrated tumor reduction in all six patients when combined with cemiplimab, including confirmed partial responses and activity in brain metastases.

Merus announced that 79% of patients with newly diagnosed metastatic head and neck cancer survived at least one year when treated with petosemtamab in combination with Keytruda.

Merus will present updated interim Phase 2 data on petosemtamab combined with pembrolizumab for first-line treatment of PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma at the 2025 ASCO Annual Meeting.

Merus N.V.'s petosemtamab receives FDA Breakthrough Therapy designation for first-line treatment of PD-L1 positive head and neck cancer when combined with pembrolizumab.

Merus N.V. has initiated a Phase 2 clinical trial of petosemtamab as a monotherapy for patients with heavily pretreated (3L+) metastatic colorectal cancer (mCRC).

The multispecific antibodies market has surpassed $8.6 billion in sales as of Q3 2024, with 16 approved therapies demonstrating efficacy across oncology and other therapeutic areas.

• Merus N.V. has received FDA approval for Bizengri, its first commercial product, targeting NRG1 gene fusions in various cancers. • Bizengri offers a new treatment option for patients with aggressive cancers who have progressed despite prior systemic therapies. • Merus has partnered with Partner Therapeutics, Inc. for the commercialization of zenocutuzumab (Zeno) in the U.S. for NRG1 fusion-positive cancers.

AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan demonstrated tumor control for a median of six months in EGFR-mutated non-small cell lung cancer (NSCLC).

The FDA granted accelerated approval to Bizengri (zenocutuzumab-zbco) for NRG1 fusion-positive NSCLC and pancreatic adenocarcinoma, marking the first systemic therapy for these cancers.

Merus' petosemtamab demonstrates a 42.5% overall response rate in Phase 2 trials for second-line or higher head and neck squamous cell carcinoma (HNSCC).